Nabi Biopharmaceuticals (NASDAQ:NABI)
| CAPS Rating |
|
|---|---|
| Open | $1.88 |
| Previous Close | $1.87 |
| Daily Range | $1.86 - $1.89 |
| 52-Week Range | $1.50 - $5.90 |
| Market Cap | $80.62M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 98,366 |
| Average Daily Volume | 0 |
NABI
VS S&P 500 (SPY)
How do you think NABI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NABI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NABI News and Commentary
- Reshuffling Yahoo!'s Board: A New House of Cards? – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- These 2 Biotechs Are Dangerous Investments – The Motley Fool
- Free Cash, But Be Careful – The Motley Fool
- Nabi Biopharma Smoking Cessation Treatment Fails In Phase III Trials – SmartMoney
- 5-Star Stocks Poised to Pop: Nabi Biopharmaceuticals – The Motley Fool
- Dan Loeb's Brilliant Stock Picks – SeekingAlpha
- The Fool Looks Ahead – The Motley Fool
- Third Point Trims Position in Nabi Biopharmaceuticals – SeekingAlpha
- Health Care Conference Highlights Speculative Innovators – BloggingStocks
- Four Small Cap Healthcare Breakouts – SeekingAlpha
- Stocks the Investing Legends Are Buying – The Motley Fool
- This Partnership Is Smoking! – The Motley Fool
- UPDATE 1-Nabi, Glaxo sign nicotine addiction vaccine deal – Reuters
- GlaxoSmithKline, Nabi Biopharmactuticals In Licensing Pact – SmartMoney
- These 5 Underdogs Are No Dogs – The Motley Fool
- 5-Star Stocks on the Upswing – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- 4-Star Stocks on the Upswing – The Motley Fool
- Get Ready for the Bounce – The Motley Fool
RSS Headlines
Fool UK
